Filing Details

Accession Number:
0001209191-10-047322
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-09-23 10:18:55
Reporting Period:
2010-09-21
Filing Date:
2010-09-23
Accepted Time:
2010-09-23 10:18:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1009356 Salix Pharmaceuticals Ltd SLXP Pharmaceutical Preparations (2834) 943267443
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1212670 J Carolyn Logan 1700 Perimeter Park Drive
Morrisville NC 27560
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-09-21 14,000 $42.35 752,007 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,770 Indirect By Son (Parker)
Common Stock 3,770 Indirect By Son (Jonathan)
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Option to Buy Common Stock $17.63 2015-06-09 44,000 44,000 Direct
Common Stock Option to Buy Common Stock $18.87 2014-06-17 33,750 33,750 Direct
Common Stock Option to Buy Common Stock $18.87 2014-06-17 65,625 65,625 Direct
Common Stock Option to Buy Common Stock $7.60 2013-07-24 33,750 33,750 Direct
Common Stock Option to Buy Common Stock $4.07 2012-07-01 285,000 285,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2015-06-09 44,000 44,000 Direct
2014-06-17 33,750 33,750 Direct
2014-06-17 65,625 65,625 Direct
2013-07-24 33,750 33,750 Direct
2012-07-01 285,000 285,000 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.29 to $42.41, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. Options are 100% vested.